Fig. 6: Determination of ecto-GPR37 in CSF of patients with Parkinson’s disease.
From: GPR37 processing in neurodegeneration: a potential marker for Parkinson’s Disease progression rate
A Concentration of ecto-GPR37 peptides in cerebrospinal fluid (CSF) from neurological controls (NCs) and patients with Parkinson’s disease (PD) patients with slow or rapid disease progression. **P < 0.01, one-way ANOVA followed by Tukey’s multiple comparison test. ROC curve analysis of CSF ecto-GPR37 comparing NC and PD slow (B) or PD rapid (C) and PD slow and rapid between them (D). The Area Under the Curve (AUC) and the p-value is indicated for each ROC curve.
